Healthcare providers increasingly rely on GLP-1 agonists in tandem with other diabetes and obesity interventions, to get better therapeutic results and steadier disease management
Ready to reclaim your energy and feel confident in your body again
LL-37: The Skin's First Responder and Immunomodulator Our bodies are incredibly smart
Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization
EMC subscribed CAD $671,356 for 1,342,712 common shares in the Companys LIFE offering that closed July 15, 2026, and separately holds 1,000,000 shares acquired through a private transaction, for total holdings of 2,342,712 shares, and has committed to hold the position while serving as the companys IR firm of record
How long should I wait after a GLP-1 injection to donate blood